In both studies, Apretude was compared to Truvada, an HIV PrEP regimen recommended by ... than Truvada for preventing HIV. The main side effects reported by patients receiving Apretude were ...

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a brand-name tablet prescribed for HIV-1. As with other drugs, Biktarvy can cause side effects, such as ...

And although some Part D plans had been paying for the long-acting PrEP anyway, others had not been, explained Schmid, who is executive director of the HIV+Hepatitis Policy Institute in Washington ...

The benefits of any new medication have to be considered alongside any side effects ... yearly lenacapavir for PrEP worldwide, for all those who want or need PrEP.” HIV experts and health ...

GlaxoSmithKline' majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir as the first injectable for pre-exposure prophylaxis (PrEP ...

(HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association. Laura M. Mann ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a prescription drug that’s used to treat HIV. This drug can interact with other medications and some ...

ART allows people to live with few complications and minimal risk of passing HIV to others. Generally, women taking ART may have different—sometimes more severe—side effects from HIV medicines.

Student Health Services provides several services and programs that can help prevent transmission of and infection with HIV, the human immunodeficiency ... the general state of your health, possible ...

Pre-exposure prophylaxis (PrEP) with antiretroviral medications is effective in preventing HIV infections. PrEP use has increased between 2013 and 2023. Multiple PrEP medications are available in ...